Yellow fever study : expansion of patient categories

The study with adult participants has been completed and the results confirm that for the four WHO prequalified vaccines, injecting only 1/5th of the dose produces a satisfactory immune response comparable to that produced by a standard dose. Following these results, the study continued with the inclusion of a more fragile population, namely HIV+ adults at the Kilifi site, Kenya and children over 5 years of age at the Mbarara site, Uganda. In 250 HIV+ adults and 420 children have been recruited and are currently completing their follow-up.